FIGARO-DKD
2021
Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease
In 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.
Result
Efficacy: CV death, MI, stroke or HF hospitalisationHR 0.87 (95% CI 0.76-0.98) · P = 0.03
Below 1 favours finerenone, above 1 favours placebo.
- Absolute difference
- 1.8 points
- NNT
- 56
Absolute difference and NNT are derived from the event rates.
- Subtopic
- Nonsteroidal MRA
- Design
- Double-blind RCT, median 3.4-year follow-up
- Relevance
- Important: one of several pillars.
- Source
- Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263.doi 10.1056/NEJMoa2110956
Discussion & critique
Confirmed the cardiovascular benefit of finerenone across the milder end of the CKD spectrum; pooled with FIDELIO in the FIDELITY analysis.